Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)

Volker Heinemann(Comprehensive Cancer Center Vienna), Ulrich Mansmann(Zimmer Biomet (Netherlands)), Clemens Gießen-Jung, Sebastian Stintzing(University of Southern California), Dominik Paul Modest, Marlies Michl(LMU Klinikum)

European Journal of Cancer

July 15, 2015

10.1016/j.ejca.2015.06.116

Cited by 185

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

|The Lancet|2019|2.6k

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

|The Lancet Oncology|2014|1.7k

2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery

|European Heart Journal|2022|1.1k

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer

|JAMA Oncology|2016|722

The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials

|European Journal of Cancer|2016|533